Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25951271 | 1.00 | KDM4E (0.37) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL26080511 | 0.99 | KDM4E (0.36) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL26080530 | 0.97 | KDM4E (0.38) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL22019522 | 0.96 | KDM4E (0.35) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL24184441 | 0.96 | KDM4E (0.38) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL25946060 | 0.95 | KDM4E (0.36) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL23947429 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL23947854 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL24152983 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1PDE1BPDE3A | |
| SCHEMBL27021083 | 0.93 | KDM4E (0.35) | KDM4EATML3MBTL1PDE1BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312538-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | KDM4E 2539/4885ATM 3031/4885L3MBTL1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.